Cargando…
Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities
Drug incompatibilities are considered as one of the most critical problems in intensive care units. In the current study, the ability of nanomaterials to prevent drug incompatibilities in clinical settings has been investigated. As a proof-of-concept, the ability of niosomes to prevent physical and...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524940/ https://www.ncbi.nlm.nih.gov/pubmed/28740102 http://dx.doi.org/10.1038/s41598-017-06955-w |
_version_ | 1783252556242223104 |
---|---|
author | Mohamed, Hebatallah B. El-Shanawany, Sohair M. Hamad, Mostafa A. Elsabahy, Mahmoud |
author_facet | Mohamed, Hebatallah B. El-Shanawany, Sohair M. Hamad, Mostafa A. Elsabahy, Mahmoud |
author_sort | Mohamed, Hebatallah B. |
collection | PubMed |
description | Drug incompatibilities are considered as one of the most critical problems in intensive care units. In the current study, the ability of nanomaterials to prevent drug incompatibilities in clinical settings has been investigated. As a proof-of-concept, the ability of niosomes to prevent physical and chemical incompatibilities that occur upon mixing acyclovir and vancomycin during management of acute meningitis has been explored. Nanosized spherical particles loaded separately with either vancomycin or acyclovir, with high entrapment efficiency (ca. 46–56%), could be prepared, and sustained release of their entrapped cargoes have been demonstrated over time. We have shown that precipitation, degradation and loss of biological activity of drugs occurred upon mixing solutions of the free drugs. On the contrary, drugs loaded separately inside niosomal structures exhibited high stability, exceptional physical and chemical compatibilities for up to 48 h with complete preservation of the antimicrobial activity of vancomycin. This study opens a venue for a new spectrum of applications of nanomaterials in preventing clinically significant drug incompatibilities, aiming at the reduction of adverse reactions, cost and hospitalization period, and improvement of patient compliance and therapeutic outcomes. |
format | Online Article Text |
id | pubmed-5524940 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-55249402017-07-26 Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities Mohamed, Hebatallah B. El-Shanawany, Sohair M. Hamad, Mostafa A. Elsabahy, Mahmoud Sci Rep Article Drug incompatibilities are considered as one of the most critical problems in intensive care units. In the current study, the ability of nanomaterials to prevent drug incompatibilities in clinical settings has been investigated. As a proof-of-concept, the ability of niosomes to prevent physical and chemical incompatibilities that occur upon mixing acyclovir and vancomycin during management of acute meningitis has been explored. Nanosized spherical particles loaded separately with either vancomycin or acyclovir, with high entrapment efficiency (ca. 46–56%), could be prepared, and sustained release of their entrapped cargoes have been demonstrated over time. We have shown that precipitation, degradation and loss of biological activity of drugs occurred upon mixing solutions of the free drugs. On the contrary, drugs loaded separately inside niosomal structures exhibited high stability, exceptional physical and chemical compatibilities for up to 48 h with complete preservation of the antimicrobial activity of vancomycin. This study opens a venue for a new spectrum of applications of nanomaterials in preventing clinically significant drug incompatibilities, aiming at the reduction of adverse reactions, cost and hospitalization period, and improvement of patient compliance and therapeutic outcomes. Nature Publishing Group UK 2017-07-24 /pmc/articles/PMC5524940/ /pubmed/28740102 http://dx.doi.org/10.1038/s41598-017-06955-w Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Mohamed, Hebatallah B. El-Shanawany, Sohair M. Hamad, Mostafa A. Elsabahy, Mahmoud Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities |
title | Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities |
title_full | Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities |
title_fullStr | Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities |
title_full_unstemmed | Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities |
title_short | Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities |
title_sort | niosomes: a strategy toward prevention of clinically significant drug incompatibilities |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524940/ https://www.ncbi.nlm.nih.gov/pubmed/28740102 http://dx.doi.org/10.1038/s41598-017-06955-w |
work_keys_str_mv | AT mohamedhebatallahb niosomesastrategytowardpreventionofclinicallysignificantdrugincompatibilities AT elshanawanysohairm niosomesastrategytowardpreventionofclinicallysignificantdrugincompatibilities AT hamadmostafaa niosomesastrategytowardpreventionofclinicallysignificantdrugincompatibilities AT elsabahymahmoud niosomesastrategytowardpreventionofclinicallysignificantdrugincompatibilities |